Personalised medicine for multiple sclerosis care
Authors:
Open Access
- 28 September 2016
- journal article
- review article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 23 (3) , 362-369
Abstract
Treatments with a range of efficacy and risk of adverse events have become available for the management of multiple sclerosis (MS). However, now the heterogeneity of clinical expression and responses to treatment pose major challenges to improving patient care. Selecting and managing the drug best balancing benefit and risk demands a new focus on the individual patient. Personalised medicine for MS is based on improving the precision of diagnosis for each patient in order to capture prognosis and provide an evidence-based framework for predicting treatment response and personalising patient monitoring. It involves development of predictive models involving the integration of clinical and biological data with an understanding of the impact of disease on the lives of individual patients. Here, we provide a brief, selective review of challenges to personalisation of the management of MS and suggest an agenda for stakeholder engagement and research to address them.Keywords
This publication has 45 references indexed in Scilit:
- Biologic efficacy optimization—a step towards personalized medicineRheumatology, 2015
- Immune biomarkers: the promises and pitfalls of personalized medicineNature Reviews Immunology, 2015
- Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathwaysScience, 2015
- Economic costs associated with an MS relapseMultiple Sclerosis and Related Disorders, 2014
- Rheumatoid Arthritis Clinical Benefits from Abatacept, Cytokine Blockers, and Rituximab Are All Linked to Modulation of Memory B Cell ResponsesThe Journal of Rheumatology, 2014
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Personalized medicine in oncology: the future is nowNature Reviews Drug Discovery, 2010
- Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2009
- Review: Neutralizing antibodies against interferon-betaTherapeutic Advances in Neurological Disorders, 2008
- The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis RegisterArthritis & Rheumatism, 2007